Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
29 juil. 2024 08h30 HE
|
Palisade Bio, Inc.
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of...
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
19 juil. 2024 08h30 HE
|
Palisade Bio, Inc.
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar...
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product
11 juil. 2024 08h00 HE
|
Palisade Bio, Inc.
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has...
Palisade Bio to Participate in the Virtual Investor Closing Bell Series
24 juin 2024 09h00 HE
|
Palisade Bio, Inc.
Live video webcast on Wednesday, June 26th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
21 juin 2024 08h15 HE
|
Palisade Bio, Inc.
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC...
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
11 juin 2024 08h30 HE
|
Palisade Bio, Inc.
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of...
Palisade Bio to Present at the Virtual Investor Pitch Conference
10 juin 2024 09h15 HE
|
Palisade Bio, Inc.
Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
21 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing...
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 08h05 HE
|
Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Palisade Bio Appoints Margery Fischbein to its Board of Directors
07 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...